TY - JOUR
T1 - Effects of retroviral infections on immune function in African-American intravenous drug users
AU - Klimas, N. G.
AU - Page, J. B.
AU - Patarca, R.
AU - Chitwood, D.
AU - Morgan, R.
AU - Fletcher, M. A.
N1 - Copyright:
Copyright 2020 Elsevier B.V., All rights reserved.
PY - 1993
Y1 - 1993
N2 - Objectives: To determine the effect of retrovirus infection and co-infection, and intravenous substance use, on immune function in African-Americans. Design: A cohort of South Florida street-recruited African-American intravenous drug users formed the study population. The cohort consisted of 90 HIV-negative & human T-lymphotropic virus (HTLV)-negative, one HIV-negative & HTLV-I-positive, 11 HIV-negative & HTLV-II-positive, 79 HIV-positive & HTLV-negative, one HIV-positive & HTLV-I-positive and 21 HIV-positive & HTLV-II-positive individuals. The results reported are for the cross-sectional, baseline assessment of immune parameters. Methods: Lymphocyte phenotypic distributions and functional markers, including proliferative response to mitogens and natural killer cell cytotoxicity, were determined. Serum immunoglobulin (Ig) levels were determined as a measure of B-cell activity. Results: HTLV-II infection was associated with increases in CDS lymphocyte count and serum Ig, but with no other significant immunologic changes. The distribution of CD4 and CDS percentages, CD4: CD8 ratio, phytohemagglutinin (PHA) and pokeweed mitogen (PWM) reactivity, IgA and IgC for the four retrovirus serostatus groups suggested the possibility of interactive effects in the co-infected group, as demonstrated by a trend toward lower medians for CD4 and for PHA and PWM response and higher medians for IgG, IgA and CD8. Retrovirus-seronegative intravenous drug users had significantly impaired immune status compared with non-drug-using control individuals. Conclusions: Immunologic dysfunction attributable to HTLV-II infection was minor compared with HIV infection in this population. Study subjects who were co-infected with HIV and HTLV demonstrated more impairment of immune function than individuals with single retrovirus infections.
AB - Objectives: To determine the effect of retrovirus infection and co-infection, and intravenous substance use, on immune function in African-Americans. Design: A cohort of South Florida street-recruited African-American intravenous drug users formed the study population. The cohort consisted of 90 HIV-negative & human T-lymphotropic virus (HTLV)-negative, one HIV-negative & HTLV-I-positive, 11 HIV-negative & HTLV-II-positive, 79 HIV-positive & HTLV-negative, one HIV-positive & HTLV-I-positive and 21 HIV-positive & HTLV-II-positive individuals. The results reported are for the cross-sectional, baseline assessment of immune parameters. Methods: Lymphocyte phenotypic distributions and functional markers, including proliferative response to mitogens and natural killer cell cytotoxicity, were determined. Serum immunoglobulin (Ig) levels were determined as a measure of B-cell activity. Results: HTLV-II infection was associated with increases in CDS lymphocyte count and serum Ig, but with no other significant immunologic changes. The distribution of CD4 and CDS percentages, CD4: CD8 ratio, phytohemagglutinin (PHA) and pokeweed mitogen (PWM) reactivity, IgA and IgC for the four retrovirus serostatus groups suggested the possibility of interactive effects in the co-infected group, as demonstrated by a trend toward lower medians for CD4 and for PHA and PWM response and higher medians for IgG, IgA and CD8. Retrovirus-seronegative intravenous drug users had significantly impaired immune status compared with non-drug-using control individuals. Conclusions: Immunologic dysfunction attributable to HTLV-II infection was minor compared with HIV infection in this population. Study subjects who were co-infected with HIV and HTLV demonstrated more impairment of immune function than individuals with single retrovirus infections.
KW - Co-infection
KW - Human T-lymphotropic virus
KW - Immune function
KW - Intravenous substance abuse
UR - http://www.scopus.com/inward/record.url?scp=0027476735&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0027476735&partnerID=8YFLogxK
U2 - 10.1097/00002030-199303000-00004
DO - 10.1097/00002030-199303000-00004
M3 - Article
C2 - 8471194
AN - SCOPUS:0027476735
VL - 7
SP - 331
EP - 335
JO - AIDS
JF - AIDS
SN - 0269-9370
IS - 3
ER -